Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or CHMP's 120-day questions, the FDA's requests stemming from the end-of-review meeting or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA or CHMP's safety concerns, that the FDA or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful.  VIVUS does not undertake an obligation to update or revise any forward-looking statements.  Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officer646-378-2923650-934-5200
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
(Date:7/24/2014)... 24, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the Company will ... 30, 2014 on Monday, August 18, 2014 for shareholders. ... ET on Monday, August 18, 2014 to discuss the ... company,s CEO, Anthony Hayes . Following ...
(Date:7/24/2014)... 24, 2014 As part of the ... in the MENA region during 2014 with potential global ... provider agreement with DZS to manage our clinical trials ... Global VP of R&D and President of SBI pharmaceuticals ... operational practices with a focus on utilizing eClinical software ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Ohio, July 8 Knowledge Enterprises, Inc.,and ... release of The,2007-2008 Orthopaedic Industry Annual Report, ... industry data. The nearly 200,page Annual Report ... to Joint Replacement, Fracture Repair, Arthroscopy/Soft,Tissue Repair, ...
... July 8 RADI Medical Systems today,announced ... guide,wire, PressureWire(R) Certus, which will begin shipments ... The latest generation of the PressureWire(R) ... which provides three key,advantages for physicians. The ...
... July 8 Telik, Inc.,(Nasdaq: TELK ), ... &,Medicinal Chemistry Letters describing a novel class of ... new treatment for diabetes.,These unique compounds are the ... to optimize the original lead structure identified through,the ...
Cached Biology Technology:Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2RADI Medical Systems Launches Next Generation PressureWire(R) Certus 2Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters 2
(Date:7/24/2014)... of researchers led by the University of York has ... in the Western Indian Ocean. , The results, ... to a revolution in the management of marine protected ... than 11,000 km in the region now under ... zones of the seas and coasts designed to protect ...
(Date:7/24/2014)... Singapore have developed Asia,s first genetic test for identifying ... the cornea called corneal stromal dystrophy which can lead ... the POLARIS TGFBI (Transforming Growth Factor beta Induced) test, ... diagnosis and management of patients with corneal stromal dystrophies. ... mutation who may also be at risk of developing ...
(Date:7/23/2014)... new study of identical twins has found that early ... study, in the journal Child Development , was ... King,s College London. , "Since reading is an ability ... reading instruction," according to Stuart J. Ritchie, research fellow ... the study. "Early remediation of reading problems might aid ...
Breaking Biology News(10 mins):Western Indian Ocean communities play vital role in conservation 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3Stronger early reading skills predict higher intelligence later 2
... may plead, cajole or entice their children to try new foods, ... University of North Carolina at Chapel Hill reveals that the reason ... on their plate and more to do with their genes. ... at UNC,s Gillings School of Global Public Health, adds to the ...
... scientists led by Dr Kate Sanders from the University of ... Museum, has uncovered how some sea snakes have developed ,shrunken ... Their research is published today in the journal ... "all the better to eat you with" - would ...
... DNA sequence data is growing exponentially", says Miami University ... the genes that we identify, we have no idea ... a foreign language, waiting to be deciphered." Understanding the ... at the forefront of molecular biology. Many groups develop ...
Cached Biology News:Genes may be reason some kids are picky about food 2Scientists discover reasons behind snakes' 'shrinking heads' 2Genomic data are growing, but what do we really know? 2
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Biology Products: